Literature DB >> 26762632

Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System.

Aya Hashimoto1,2, Toshihiro Tanaka3, Masayuki Sho4, Hideyuki Nishiofuku1, Tetsuya Masada1, Takeshi Sato1, Nagaaki Marugami1, Hiroshi Anai2, Hiroshi Sakaguchi5, Masatoshi Kanno6, Tetsuro Tamamoto7, Masatoshi Hasegawa7, Yoshiyuki Nakajima4, Kimihiko Kichikawa1.   

Abstract

PURPOSE: Previous reports have shown the effectiveness of adjuvant hepatic arterial infusion chemotherapy (HAIC) in pancreatic cancer. However, percutaneous catheter placement is technically difficult after pancreatic surgery. The purpose of this study was to evaluate the feasibility and outcome of HAIC using a coaxial technique compared with conventional technique for postoperative pancreatic cancer.
MATERIALS AND METHODS: 93 consecutive patients who received percutaneous catheter-port system placement after pancreatectomy were enrolled. In 58 patients from March 2006 to August 2010 (Group A), a conventional technique with a 5-Fr indwelling catheter was used and in 35 patients from September 2010 to September 2012 (Group B), a coaxial technique with a 2.7-Fr coaxial catheter was used.
RESULTS: The overall technical success rates were 97.1 % in Group B and 86.2 % in Group A. In cases with arterial tortuousness and stenosis, the success rate was significantly higher in Group B (91.7 vs. 53.8 %; P = 0.046). Fluoroscopic and total procedure times were significantly shorter in Group B: 14.7 versus 26.7 min (P = 0.001) and 64.8 versus 80.7 min (P = 0.0051), respectively. No differences were seen in the complication rate. The 1 year liver metastasis rates were 9.9 % using the conventional system and 9.1 % using the coaxial system (P = 0.678). The overall median survival time was 44 months. There was no difference in the survival period between two systems (P = 0.312).
CONCLUSIONS: The coaxial technique is useful for catheter placement after pancreatectomy, achieving a high success rate and reducing fluoroscopic and procedure times, while maintaining the safety and efficacy for adjuvant HAIC in pancreatic cancer.

Entities:  

Keywords:  Arterial infusion chemotherapy; Liver metastases; Pancreatic cancer

Mesh:

Year:  2016        PMID: 26762632     DOI: 10.1007/s00270-016-1292-7

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

1.  Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.

Authors:  Kenji Nakagawa; Takahiro Akahori; Satoshi Nishiwada; Minako Nagai; Kota Nakamura; Toshihiro Tanaka; Tetsuro Tamamoto; Chiho Ohbayashi; Masatoshi Hasegawa; Kimihiko Kichikawa; Naoya Ikeda; Masayuki Sho
Journal:  Langenbecks Arch Surg       Date:  2018-09-15       Impact factor: 3.445

Review 2.  Making the Case: Intra-arterial Therapy for Less Common Metastases.

Authors:  Andrew C Gordon; Omar M Uddin; Ahsun Riaz; Riad Salem; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

3.  Analysis of the efficacy of transcatheter arterial infusion chemotherapy in the treatment of pancreatic carcinoma.

Authors:  Chunhui Nie; Yuelin Zhang; Guanhui Zhou; Tanyang Zhou; Tongyin Zhu; Baoquan Wang; Shengqun Chen; Hongliang Wang; Ziniu Yu; Li Jing; Junhui Sun
Journal:  J Interv Med       Date:  2020-10-17

4.  Combination of TPF regimen and cinobufotalin inhibits proliferation and induces apoptosis in human hypopharyngeal and laryngeal squamous cell carcinoma cells.

Authors:  Xixi Shen; Yong Tao; Yifan Yang; Ru Wang; Jugao Fang; Meng Lian
Journal:  Onco Targets Ther       Date:  2018-12-31       Impact factor: 4.147

5.  Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer.

Authors:  Shinya Endo; Shinya Kawaguchi; Shuzo Terada; Naofumi Shirane
Journal:  Intern Med       Date:  2020-09-19       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.